[1]王美佳,刘虹伶,曾依伶.地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究[J].陕西医学杂志,2023,52(12):1731-1734.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
　WANG Meijia,LIU Hongling,ZENG Yiling.Efficacy and safety of decitabine combined with harringtonine and cytarabine regimen in treatment of myelodysplastic syndrome[J].,2023,52(12):1731-1734.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
点击复制

地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年12期
页码:
1731-1734
栏目:
药物与临床
出版日期:
2023-12-05

文章信息/Info

Title:
Efficacy and safety of decitabine combined with harringtonine and cytarabine regimen in treatment of myelodysplastic syndrome
作者:
王美佳; 刘虹伶; 曾依伶
(成都上锦南府医院血液科,四川 成都 611743)
Author(s):
WANG Meijia; LIU Hongling; ZENG Yiling
(Department of Hematology,Chengdu Shangjin Nanfu Hospital,Chengdu 611743,China)
关键词:
骨髓增生异常综合征;  地西他滨;  三尖杉酯碱;  阿糖胞苷;  血常规;  预后
Keywords:
Myelodysplastic syndrome;  Decitabine;  Harringtonine;  Cytosine arabinoside;  Blood routine;  Prognosis
分类号:
R 551.3
DOI:
DOI:10.3969/j.issn.1000-7377.2023.12.023
文献标志码:
A
摘要:
目的:探讨地西他滨联合HA方案(三尖杉酯碱+阿糖胞苷)治疗骨髓增生异常综合征(MDS)的疗效及安全性。方法:选取MDS患者94例,随机分为对照组和观察组,每组47例。对照组给予HA方案治疗,观察组患者在HA方案基础上联合地西他滨治疗。两组患者均治疗4个疗程。比较两组患者临床疗效、治疗前后血常规指标[红细胞计数(RBC)、平均红细胞体积(MCV)、血小板(PLT)、血红蛋白(HGB)、白细胞计数(WBC)、中性粒细胞计数(NEU)]、预后及不良反应发生情况。结果:观察组疾病控制率高于对照组(P<0.05)。与组内治疗前比较,对照组治疗后PLT和HGB升高,WBC和NEU降低(均P<0.05); 观察组治疗后RBC、MCV、PLT和HGB升高,WBC和NEU降低(均P<0.05)。与对照组比较,观察组治疗后RBC、MCV、PLT和HGB升高,WBC和NEU降低(均P<0.05)。治疗后,观察组患者预后情况优于对照组(P<0.05)。两组患者不良反应总发生率比较差异无统计学意义(P>0.05)。结论:地西他滨联合HA方案治疗MDS可协同增效,改善患者血常规指标与预后情况,且安全性较好。
Abstract:
Objective:To investigate the efficacy and safety of decitabine combined with HA regimen(harringtonine and cytarabine)in the treatment of myelodysplastic syndrome(MDS).Methods:A total of 94 patients with MDS were randomly divided into a control group and an observation group,47 cases in each group.The control group was treated with HA regimen,and the observation group was treated with decitabine on the basis of HA regimen.Both groups were treated for 4 courses.The clinical efficacy,blood routine indexes(RBC,MCV,PLT,HGB,WBC,NEU)before and after treatment,prognosis and adverse reactions were compared between the two groups.Results:The disease control rate in the observation group was higher than that in the control group(P<0.05).Compared with those before treatment,PLT and HGB were increased,WBC and NEU were decreased in the control group after treatment(all P<0.05).After treatment,RBC,MCV,PLT and HGB increased,WBC and NEU decreased in the observation group(all P<0.05).Compared with the control group,RBC,MCV,PLT and HGB were increased,WBC and NEU were decreased in the observation group after treatment(all P<0.05).After treatment,the prognosis of the observation group was better than that of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Decitabine combined with HA regimen has synergistic effect in the treatment of MDS patients,improves the blood routine indexes and prognosis,and has good safety.

参考文献/References:

[1] 董 曼,王月莉.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响[J].陕西医学杂志,2021,50(6):657-659,663.
[2] 张文荟,陈香丽,裴晓杭,等.骨髓增生异常综合征-难治性贫血伴原始细胞增多患者应用重组人血小板生成素对地西他滨联合预激方案治疗效果的影响[J].中华实用诊断与治疗杂志,2020,34(1):81-84.
[3] 杨 斐,施 均.骨髓增生异常综合征病理机制及靶向药物治疗[J].中国实用内科杂志,2022,42(7):552-556.
[4] 李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135-1138,1142.
[5] 刘 欣,刘艳芬,孙 旭,等.血速升颗粒联合复方黄黛片治疗骨髓增生异常综合征化疗相关血细胞减少临床研究[J].陕西中医,2021,42(1):78-80.
[6] 刘 月,曹 阳,谢晓宝,等.地西他滨联合全反式维甲酸或半量预激方案治疗老年骨髓增生异常综合征和急性髓系白血病的疗效及安全性比较[J].医学研究生学报,2019,32(5):511-517.
[7] 胡 芮,高 媛,闻 艳,等.地西他滨对骨髓增生异常综合征/急性髓系白血病患者外周血及骨髓中调节性T细胞相对含量的影响研究[J].中国实验血液学杂志,2022,30(1):36-42.
[8] 王晗晗,许 力,武琳琳,等.地西他滨单药及联合半程和全程HA方案治疗骨髓增生异常综合征和急性髓系白血病的效果[J].现代生物医学进展,2021,21(1):150-153.
[9] 中华医学会血液学分会.骨髓增生异常综合征诊断与治疗中国专家共识(2014年版)[J].中华血液学杂志,2014,35(11):1042-1048.
[10] 张之南,沈 悌.血液病诊断及疗效标准[M].2版.北京:科学出版社,1998:188-214.
[11] 尹婉宜,沈 扬,张丽红,等.青黄散加解毒化瘀方治疗骨髓增生异常综合征疗效及对患者血清可溶性细胞间黏附分子-1、转化生长因子-β1的影响[J].陕西中医,2022,43(8):1056-1059.
[12] 李清群,彭志元,高 陆,等.骨髓增生异常综合征并离心性环状红斑一例[J].海南医学,2022,33(13):1754-1756.
[13] 凌奕文,叶海燕,赵 莹,等.地西他滨联合预激方案初治高危骨髓增生异常综合征及老年急性髓系白血病的临床观察[J].现代肿瘤医学,2019,27(2):321-324.
[14] 张彦平,刘蒙蒙,展新荣.地西他滨联合小剂量高三尖杉酯碱和阿糖胞苷治疗老年急性髓系白血病疗效观察[J].新乡医学院学报,2020,37(11):1068-1070,1074.
[15] 龚 辉,陈 姣,杜 芳,等.地西他滨联合半量CAG方案治疗骨髓增生异常综合征-伴原始细胞增多和急性髓细胞白血病的疗效分析[J].内科急危重症杂志,2019,25(3):206-209.
[16] 岳 雪,王浩凌,肖莲春,等.HAG方案联合地西他滨治疗骨髓增生异常综合征患者的近、远期疗效观察[J].中国煤炭工业医学杂志,2022,25(1):77-81.
[17] 胡通林,郑智茵,沈建平,等.地西他滨治疗中高危骨髓增生异常综合征的疗效分析[J].中华全科医学,2020,18(4):552-554,689.
[18] 童 春,叶 芳,李宁宁,等.不同剂量地西他滨治疗高危骨髓增生异常综合征患者疗效及安全性的回顾性分析[J].中国实验血液学杂志,2021,29(6):1845-1850.
[19] 杨 倩,聂淑敏,黄俊霞,等.地西他滨为主方案治疗中高危骨髓增生异常综合征患者的病态造血变化及预后价值分析[J].临床血液学杂志,2020,33(3):191-194.
[20] 郑 琳,陈 果.地西他滨单药或联合CAG方案治疗高危骨髓增生异常综合征的疗效及安全性分析[J].实用医院临床杂志,2018,15(6):87-90.

相似文献/References:

[1]聂泽强,李晓云,马爻芳,等.WT1基因在骨髓增生异常综合征患者外同血中的表达及临床意义[J].陕西医学杂志,2019,(8):977.
　NIE Zeqiang,LI Xiaoyun,MA Yaofang,et al.Expression of WT1 gene in patients with Myelodysplastic syndrome[J].,2019,(12):977.
[2]李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
　LI Zhenbo,LU Cheng.Efficacy and safety of azacitidine in treatment of MDS with ASXL1 gene mutation[J].,2021,50(12):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
[3]李荣芳,金 龙,赵立丹.外周血T细胞免疫球蛋白黏蛋白-3和血清乳酸脱氢酶联合检测在骨髓增生异常综合征诊断中的应用价值[J].陕西医学杂志,2021,50(9):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
　LI Rongfang,JIN Long,ZHAO Lidan.Application value of combined detection of peripheral blood TIM-3 and serum LDH in diagnosis of MDS[J].,2021,50(12):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
[4]马丽丽,付长江.存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究[J].陕西医学杂志,2024,(3):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
　MA Lili,FU Changjiang.Clinical value of Survivin and P15INK4B in diagnosis of myelodysplastic syndrome and prognosis evaluation of patients[J].,2024,(12):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
[5]董 曼,王月莉.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响[J].陕西医学杂志,2021,50(6):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
　DONG Man,WANG Yueli.Effects of different doses of decitabine on Beclin1 protein expression in mice with myelodysplastic syndrome[J].,2021,50(12):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]

备注/Memo

备注/Memo:
基金项目:四川省科技计划项目(2018SZ0200)
更新日期/Last Update: 2023-12-05